CN115315292A - 具有硫氧还蛋白活性的组合物及相关方法 - Google Patents

具有硫氧还蛋白活性的组合物及相关方法 Download PDF

Info

Publication number
CN115315292A
CN115315292A CN202180018760.3A CN202180018760A CN115315292A CN 115315292 A CN115315292 A CN 115315292A CN 202180018760 A CN202180018760 A CN 202180018760A CN 115315292 A CN115315292 A CN 115315292A
Authority
CN
China
Prior art keywords
thioredoxin
protein
composition
peptide
active site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018760.3A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·B·海菲茨
哈伊姆·莫斯科维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opro Therapeutics
Original Assignee
Opro Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opro Therapeutics filed Critical Opro Therapeutics
Publication of CN115315292A publication Critical patent/CN115315292A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CN202180018760.3A 2020-01-03 2021-01-04 具有硫氧还蛋白活性的组合物及相关方法 Pending CN115315292A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956994P 2020-01-03 2020-01-03
US62/956,994 2020-01-03
PCT/US2021/012109 WO2021138682A1 (en) 2020-01-03 2021-01-04 Compositions having thioredoxin activity and related methods

Publications (1)

Publication Number Publication Date
CN115315292A true CN115315292A (zh) 2022-11-08

Family

ID=76687128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018760.3A Pending CN115315292A (zh) 2020-01-03 2021-01-04 具有硫氧还蛋白活性的组合物及相关方法

Country Status (6)

Country Link
US (1) US20230071765A1 (https=)
EP (1) EP4084867A4 (https=)
JP (2) JP2023509462A (https=)
CN (1) CN115315292A (https=)
CA (1) CA3163157A1 (https=)
WO (1) WO2021138682A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968481B1 (en) 2013-03-15 2020-11-04 Orpro Therapeutics Inc. Product and process for mucus viscosity normalization
CN115768865A (zh) * 2020-06-23 2023-03-07 松下知识产权经营株式会社 过敏原的灭活方法及过敏原灭活装置
CN119317716A (zh) * 2022-07-05 2025-01-14 国立大学法人东北大学 抗病毒剂、用于治疗或者预防病毒感染症的药物组合物、病毒感染症的重症化风险的评价试剂盒以及病毒感染症的重症化风险的评价方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
JPH10191977A (ja) * 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
JP4758525B2 (ja) * 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
WO2004013283A2 (en) * 2002-08-02 2004-02-12 University Of Rochester Thioredoxin mutants and uses thereof
JP4273234B2 (ja) * 2003-03-31 2009-06-03 独立行政法人産業技術総合研究所 チオレドキシン改変体
WO2005121329A2 (en) * 2004-06-11 2005-12-22 Syngenta Limited Method for ameliorating an inflammatory skin condition
CN107625958A (zh) * 2011-05-17 2018-01-26 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
EP2968481B1 (en) * 2013-03-15 2020-11-04 Orpro Therapeutics Inc. Product and process for mucus viscosity normalization
WO2019222665A1 (en) * 2018-05-17 2019-11-21 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions

Also Published As

Publication number Publication date
US20230071765A1 (en) 2023-03-09
CA3163157A1 (en) 2021-07-08
JP2025182217A (ja) 2025-12-12
EP4084867A4 (en) 2024-01-24
EP4084867A1 (en) 2022-11-09
WO2021138682A1 (en) 2021-07-08
JP2023509462A (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
US20260027189A1 (en) Product and process for mucus viscosity normalization
AU2020203183B2 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
JP2025182217A (ja) チオレドキシン活性を有する組成物および関連方法
CN108368165A (zh) 用于治疗颅内出血相关症状的方法和组合物
KR20050072743A (ko) 점액 또는 타액의 액화를 위한 생성물 및 방법
PT2621515T (pt) Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
EP3900735A1 (en) Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor
US10683333B2 (en) Islet amyloid polypeptides with improved solubility
US20130131192A1 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
HK40081004A (en) Compositions having thioredoxin activity and related methods
CN108434439B (zh) 钙网蛋白的医药用途
US11028137B2 (en) Mutant islet amyloid polypeptides with improved solubility and methods for using the same
HK1220354B (en) Product and process for mucus viscosity normalization
NZ711983B2 (en) Product and process for mucus viscosity normalization
HK40060818A (en) Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081004

Country of ref document: HK